Flutemetamol (18F)
Systematic (IUPAC) name | |
---|---|
2-[3-(18F)Fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol | |
Clinical data | |
Trade names | Vizamyl |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Legal status |
|
Routes of administration | Intravenous |
Identifiers | |
ATC code | V09AX04 |
PubChem | CID 15950376 |
ChemSpider | 13092196 |
UNII | 0F3M7032P5 |
ChEBI | CHEBI:76611 |
Chemical data | |
Formula | C14H1118FN2OS |
Molar mass | 273.316 g/mol |
| |
|
Flutemetamol (18F) (trade name Vizamyl, by GE Healthcare) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18, used as a diagnostic tool for Alzheimer's disease.[1]
Mechanism of action
After the substance is given intravenously, it accumulates in beta amyloid plaques in the patient's brain, which thus become visible via positron emission tomography (PET).[1]
References
This article is issued from Wikipedia - version of the Sunday, September 21, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.